Company Overview and News
Stocks were indicated higher on Tuesday after a follow-on rally failed to hold by Monday’s close. While the market’s all-time highs are still within striking distance, investors have seen lower upside from buying immediately after the big market pullbacks in 2018 than in prior years. And the financial media keeps referring to a “peak cycle” with strong earnings. Now investors have to be considering how they want to position their investments for the rest of the year and into 2019.
ABT BAC FB BAX MPC ABT ADBE EW BAC BSX TRI HRS LVS
On today’s episode of Free Lunch, Ryan McQueeney recaps morning news from Wall Street, including tensions between the U.S. and Saudi Arabia, big bank earnings, and historic data from Activision Blizzard. The host also covers the bankruptcy of Sears, September’s retail sales results, and holiday shopping expectations.
WFC WFCNP BAC C ATVI BAC SHLD SHLDW
Despite dismal investment banking and trading performance, loan growth, higher interest rates and tax cuts drove Bank of America’s (BAC - Free Report) third-quarter 2018 earnings of 66 cents per share, which handily outpaced the Zacks Consensus Estimate of 62 cents. Also, the figure was 44% higher than the prior-year quarter. Shares of BofA rose nearly 1% in the pre-market trading, indicating that investors have taken the results in their stride.
WFC WFCNP BAC C BAC GPN
Monday, October 15, 2018 Monday markets in the Far East — from Japan to Shanghai to Hong Kong to Australia — were all down overnight, spoiling the idea that a Friday resurgence in these markets was a new start of indexes ramping higher, as Q3 earnings results here at home begin to command headlines. Included among concerns across the Pacific are the significant ties of Asian banks with the kingdom of Saudi Arabia, currently under fire for the disappearance of a Saudi journalist who had been critical of the kingdom in his articles in the Washington Post.
Monday markets in the Far East — from Japan to Shanghai to Hong Kong to Australia — were all down overnight, spoiling the idea that a Friday resurgence in these markets was a new start of indexes ramping higher, as Q3 earnings results here at home begin to command headlines. Included among concerns across the Pacific are the significant ties of Asian banks with the kingdom of Saudi Arabia, currently under fire for the disappearance of a Saudi journalist who had been critical of the kingdom in his articles in the Washington Post.
Chicago, IL – October 15, 2018 – Today, Zacks Investment Ideas feature highlights Features: JP Morgan Chase (JPM - Free Report) ), Citigroup (C - Free Report) ), Wells Fargo (WFC - Free Report) ), Bank of America (BAC - Free Report) ) and Bank of New York Mellon (BK - Free Report) .
WFC WFCNP BAC C BAC BK VSH HEAR
Bank of America Corp. (NYSE: BAC) released its third-quarter earnings report before the markets opened on Monday. The company said that it had $0.66 in earnings per share (EPS) and $22.8 billion in revenue, which compares with consensus estimates of $0.62 in EPS and $22.7 billion in revenue. In the same period of last year, the bank said it EPS of had $0.48 on $21.8 billion in revenue.
Have you been eager to see how Bank of America (BAC - Free Report) performed in Q3 in comparison with the market expectations? Let’s quickly scan through the key facts from this Charlotte-based one of the world's largest financial institutions’ earnings release this morning: An Earnings Beat BofA came out with earnings of 66 cents per share, which surpassed the Zacks Consensus Estimate of 62 cents.
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LSE:BAC / BANK OF AMERICA CORP on message board site Silicon Investor.